AUROPHARMA:NSE-Aurobindo Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 673.55

Change

+10.95 (+1.65)%

Market Cap

INR 386.87B

Volume

1.47M

Avg Analyst Target

INR 879.42 (+30.56%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aurobindo Pharma Limited (AUROPHARMA) Stock Analysis:
Based on the Aurobindo Pharma Limited stock forecasts from 10 analysts, the average analyst target price for Aurobindo Pharma Limited is INR 879.42 over the next 12 months. Aurobindo Pharma Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Aurobindo Pharma Limited is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Aurobindo Pharma Limited’s stock price was INR 673.55. Aurobindo Pharma Limited’s stock price has changed by +4.65 % over the past week, -17.65 % over the past month and -25.01 % over the last year.

About

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, over the counter drugs, and dietary supplement ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+20.90 (+2.80%)

INR1,808.14B 29.97 18.57
DIVISLAB:NSE Divi's Laboratories Limited

+25.10 (+0.53%)

INR1,295.17B 60.63 39.54
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+56.40 (+1.22%)

INR775.58B 39.98 18.56
PEL:NSE Piramal Enterprises Limited

+41.20 (+1.66%)

INR577.17B 49.59 14.15
CADILAHC:NSE Cadila Healthcare Limited

+6.35 (+1.40%)

INR476.30B 9.93 13.79
ALKEM:NSE Alkem Laboratories Limited

+32.30 (+0.94%)

INR429.65B 25.23 18.39
LUPIN:NSE Lupin Limited

+4.20 (+0.48%)

INR401.78B 25.10 32.25
LAURUSLABS:NSE Laurus Labs Limited

+8.50 (+1.67%)

INR272.94B 27.08 17.40
IPCALAB:NSE Ipca Laboratories Limited

+3.30 (+0.16%)

INR266.41B 54.17 17.46
AJANTPHARM:NSE Ajanta Pharma Limited

+38.35 (+1.84%)

INR180.02B 25.57 16.60

ETFs Containing AUROPHARMA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.40% 12% F 5% F
Dividend Return 0.49% 38% F 23% F
Total Return -26.91% 12% F 5% F
Trailing 12 Months  
Capital Gain -25.01% 14% F 4% F
Dividend Return 0.50% 35% F 22% F
Total Return -24.51% 14% F 5% F
Trailing 5 Years  
Capital Gain -6.39% 30% F 37% F
Dividend Return 2.02% 35% F 22% F
Total Return -4.38% 30% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 12.26% 29% F 47% F
Dividend Return 0.42% 44% F 33% F
Total Return 12.69% 28% F 47% F
Risk Return Profile  
Volatility (Standard Deviation) 39.89% 75% C 71% C-
Risk Adjusted Return 31.81% 40% F 57% F
Market Capitalization 386.87B 90% A- 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.42 91% A- 81% B-
Price/Book Ratio 1.70 75% C 55% F
Price / Cash Flow Ratio 11.62 63% D 41% F
EV/EBITDA 4.87 92% A- 86% B
Management Effectiveness  
Return on Equity 24.95% 89% B+ 86% B
Return on Invested Capital 9.19% 43% F 66% D
Return on Assets 7.94% 61% D- 74% C
Debt to Equity Ratio 0.77% 65% D 77% C+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.74 51% F 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.